VolitionRx Publishes Report on Veterinary Cancer Screening Test
VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has published a report with contributions from four global leaders in veterinary oncology, ahead of the expected launch of its first product, the Nu.Q Vet Cancer Screening Test.
The comprehensive new report for veterinarians, titled “A Look to the Future of Cancer Diagnostics,” explores the promise of molecular diagnostics in veterinary oncology, especially for hard to find tumors and introduces Volition’s Nu.Q technology and Nu.Q Vet Cancer Screening Test.
The report is the outcome of a round table event, hosted by Volition Veterinary Diagnostics Development, LLC, with an expert panel including: Dr. Tim Fan, Program Leader, Cancer Discovery Platforms and Professor, Veterinary Clinical Medicine, at the Cancer Center at Illinois; Dr. David Vail, Professor and Barbara A. Suran Chair in Comparative Oncology and Director of the Barbara A. Suran Comparative Oncology Research Center; and Dr. Sue Ettinger, a practicing veterinary cancer specialist, international speaker and author. Dr. Heather Wilson-Robles, Professor of Oncology at Texas A&M University and Chief Medical Officer at Volition Veterinary was also a panelist.
The panel reviewed data from results presented at the Veterinary Cancer Society Virtual Annual Conference in October, which demonstrated the successful use of the blood-based Nu.Q Vet Cancer Screening Test for dogs with lymphoma and hemangiosarcoma, a cancer of blood vessel walls, which together make up approximately one-third of canine cancers. They also discussed topics including the potential of early cancer diagnosis to help improve the treatment and quality of life, as well as supporting the clinical decision-making process.
“I was very pleased to participate in the round table and the subsequent report,” Fan said. “Volition’s platform is very exciting. Nucleosomes are very stable biomarkers that can be found in circulation and bringing this technology to the veterinary market is a very important first step. I look forward to seeing Volition adapt to the needs of the clients, pets and pet-owners that will benefit from this diagnostic test.”
Wilson-Robles said: “Dr. Fan, Dr. Vail and Dr. Ettinger are leading the field in veterinary oncology. I am hugely grateful for their insight, expert opinion and guidance at this key moment as we prepare for the launch of our first product and take on the challenge of earlier detection of canine cancers. Cancer screening is not as commonplace in animal health as it is in human health, but blood tests like the Nu.Q Vet Cancer Screening Test could transform how we manage cancer in companion animals.”